CN109549997A - A kind of drug for treating rheumatism bone disease - Google Patents
A kind of drug for treating rheumatism bone disease Download PDFInfo
- Publication number
- CN109549997A CN109549997A CN201710873206.9A CN201710873206A CN109549997A CN 109549997 A CN109549997 A CN 109549997A CN 201710873206 A CN201710873206 A CN 201710873206A CN 109549997 A CN109549997 A CN 109549997A
- Authority
- CN
- China
- Prior art keywords
- parts
- drug
- bone disease
- rheumatism bone
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 229940079593 drug Drugs 0.000 title claims abstract description 43
- 208000020084 Bone disease Diseases 0.000 title claims abstract description 30
- 206010047700 Vomiting Diseases 0.000 claims abstract description 13
- 230000008673 vomiting Effects 0.000 claims abstract description 13
- 241000258920 Chilopoda Species 0.000 claims abstract description 12
- 241001465251 Ephedra sinica Species 0.000 claims abstract description 11
- 241000237636 Pheretima Species 0.000 claims abstract description 11
- 241000270295 Serpentes Species 0.000 claims abstract description 11
- 241000717739 Boswellia sacra Species 0.000 claims abstract description 10
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 10
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 10
- 239000004863 Frankincense Substances 0.000 claims abstract description 10
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 241001043298 Croton draco Species 0.000 claims abstract description 9
- 239000009136 dragon's blood Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 239000012530 fluid Substances 0.000 claims description 9
- 235000020097 white wine Nutrition 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 235000014101 wine Nutrition 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 238000013329 compounding Methods 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 241001314440 Triphora trianthophoros Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000012232 skeletal muscle contraction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of drugs for treating rheumatism bone disease, it belongs to pharmaceutical compounding techniques field.The drug of the described treatment rheumatism bone disease includes following raw material: 20-30 part of Chinese ephedra, river be 15-20 parts attached, 20-30 parts of olibanum, 10-15 parts of myrrh, 10-15 parts of first tail, 8-15 parts of Eupolyphoge sinensis, worm 10-15 parts complete, 8-15 parts of pheretima, 3-8 parts of centipede, crow 3-8 parts of snake, 2-5 parts of dragon's blood, 40-50 parts of vomiting nut.Such treatment rheumatism bone disease medicament composing prescription science, preparation method is unique, and dose facilitates less, and convenient for saving, drug effect is obvious, popularization easy to produce, and safely controllable, can eradicate rheumatism bone disease various symptoms, and cure rate is up to 98% or more.
Description
Technical field:
The present invention relates to a kind of drugs for treating rheumatism bone disease, belong to pharmaceutical compounding techniques field.
Background technique:
Rheumatism, rheumatoid, protrusion of lumber intervertebral disc, osteoproliferation, sciatica, ankylosing spondylitis, cervical spondylosis, shoulder
Inflammation, arthritis, gout, hemiplegia etc. are all common disease, frequently-occurring disease, and it is swollen, numb, living to show as local pain, acid by patient when morbidity
Dynamic limited, red and swollen fever, nerve compression meeting shadow plays muscular atrophy paralysis when serious.Currently, the drug for the treatment of rheumatic disease can
It is divided into following several classes: 1. nonsteroidal anti-inflammatory agents (NSAIDs)；2. cortex hormone of aadrenaline: it is primarily referred to as glucocorticoid, because
This kind of drug has anti-inflammatory and immunosuppressive action, has relatively strong and quickly diminishes inflammation and inflammatory reaction bring various symptoms,
Such as fever, arthroncus and pain.So being often used as First Line drug to various rheumatic diseases.That clinically applies has
It is short-acting, middle effect and long-acting equal preparations, but since it not eradicates drug, long-term largely uses can induce infection, osteoporosis, stock
Head necrosis, diabetes, peptic ulcer, hypertension, insanity etc.；And be such as discontinued it is too fast be also easy to produce state of an illness rebound phenomenon,
Therefore should be noted that according to disease and the state of an illness, adjust the type and dosage for using drug.In addition to patient with severe symptoms, in principle with low dose,
Low doses are advisable.3. the also known as slow effect antirheumatic of the antirheumatic for improving the state of an illness.Such drug includes numerous species
Structure is different, acts on different drug.Their general character is that action is slow, there is certain cumulative effect, therefore after being discontinued, effect disappears
Mistake is also relatively slow, can still maintain a period of time.They have no the effect of direct anti-inflammatory analgetic, but can be played by different mechanism anti-
Scorching and immune or immunosuppressive action.The above various drugs internal organs (liver, kidney, bladder, lung, stomach and intestine, the reproduction important to human body
Gland) and tissue (marrow) toxic effect for having nothing in common with each other, there is a problem of more.In current existing technology, western medical treatment
This disease is often with the methods of anti-inflammatory analgetic, hormone, closing, ultraviolet light irradiation, traction, operation.The disadvantage is that palliative, treatment
Time is long, weak curative effect, expensive, and surgical risk is high.Therefore need to study a kind of good effect, the lesser treatment of side effect
The drug of rheumatism bone disease.
Summary of the invention:
In view of the above-mentioned problems, the technical problem to be solved in the present invention is to provide a kind of drugs for treating rheumatism bone disease.
The drug for the treatment of rheumatism bone disease of the invention includes following raw material: 20-30 parts of Chinese ephedra, river be 15-20 parts attached,
20-30 parts of olibanum, 10-15 parts of myrrh, 10-15 parts of first tail, 8-15 parts of Eupolyphoge sinensis, worm 10-15 parts complete, 8-15 parts of pheretima, centipede 3-8
Part, black 3-8 parts of snake, 2-5 parts of dragon's blood, 40-50 parts of vomiting nut；
Preferably, the drug of the treatment rheumatism bone disease includes following raw material: 25 parts of Chinese ephedra, river attached 18
Part, 25 parts of olibanum, 13 parts of myrrh, 13 parts of first tail, 12 parts of Eupolyphoge sinensis, 13 parts of full worm, 12 parts of pheretima, 5 parts of centipede, black 5 parts of snake, dragon's blood
3 parts, 45 parts of vomiting nut.
The drug for the treatment of rheumatism bone disease of the invention the preparation method comprises the following steps: according to pharmaceutical formulation ratio that 25 parts of Chinese ephedra, river is attached
18 parts, 25 parts of olibanum, 13 parts of myrrh, 13 parts of first tail, 12 parts of Eupolyphoge sinensis, 13 parts of full worm, 12 parts of pheretima, 5 parts of centipede, black 5 parts of snake, blood
It exhausts 3 parts, 45 parts of vomiting nut and is placed in water and boiled twice, mild fire boils one hour again after each intense fire water is opened, twice
It is mixed to get tanning medical fluid, boils and high spirit immersion is added in medical fluid, white wine is the wine of preferred pure grain brewing, the alcohol of white wine
Concentration is 34-53 degree, wherein the volume ratio of tanning medical fluid and white wine is 20-25: 1, both obtains drug.
Beneficial effects of the present invention: this prescription follows traditional Chinese medicine really to lead to the principle for benefit, is dispelling internal chill
When damp evil, with unobstructed channels and collaterals, warmly nourishing Yangqi not only provided the power that body resists dispeling disease and evil, but also was the unobstructed passing away of disease and evil,
To disease and evil with outlet, achieve the purpose that real righting is got rid of evils, Chinese ephedra therein, river is attached, warmly nourishing Yangqi, and sunlight one shines, haze
Disappear to the greatest extent；The full worm Eupolyphoge sinensis pheretima centipede crow snake of first tail is all animal drugs, take its walk gang up up to meaning, and have the work for searching wind and removing obstruction in channels
Cooperate other medicines of the present invention with, vomiting nut, clinical research has an excited spinal nerve, promotion Skeletal Muscle Contraction, not only can be with
Power is provided for temperature three-way meridian, while having shrinks interverbebral disc, repairs injured nerve and spinal cord effect, to disc herniation,
Myasthenia, rheumatic arthralgia, paralysis due to windstroke, spinal cord injury all has therapeutic effect, and full worm centipede has the function of relieving convulsion and spasm,
Can play the role of with vomiting nut it is opposite be multiplied, not only enhance dispeling wind and dehumidification of removing obstruction in channels to relieve pain, but also reduce vomiting nut
Side effect causes the safe synergy of the present invention, and the drug tanning time of the present invention is long, not only reduces poisonous side effect of medicine, but also can be having
Effect ingredient is sufficiently endured out, is heightened the effect of a treatment, and proper amount of white spirit is added, not only acts as wind dispelling cold dispelling, and plays the work of guidance Meridian Tropism of Herbal Drugs
With, while the fresh-keeping effect of drug is played, killing three birds with one stone, dose varies with each individual, the receiving at everyone is drunk since a small amount of
It is taken in safe range, can both distinguish different crowd, different constitutions, and can be with the treatment disease of greatest treatment efficacy.Such treatment
Rheumatism bone disease medicament composing prescription science, preparation method is unique, and dose facilitates less, and convenient for saving, drug effect is obvious, popularization easy to produce, and
And it is safely controllable, rheumatism bone disease various symptoms can be eradicated, cure rate is up to 98% or more.
Specific embodiment:
Present embodiment is described in further detail invention using following technical scheme and embodiment.
The drug that rheumatism bone disease is treated in present embodiment includes following raw material: 20-30 parts of Chinese ephedra, river are attached
15-20 parts, 20-30 parts of olibanum, 10-15 parts of myrrh, 10-15 parts of first tail, 8-15 parts of Eupolyphoge sinensis, worm 10-15 parts complete, pheretima 8-15
Part, 3-8 parts of centipede, black 3-8 parts of snake, 2-5 parts of dragon's blood, 40-50 parts of vomiting nut.
Preferably, the drug of the treatment rheumatism bone disease includes following raw material: 25 parts of Chinese ephedra, river attached 18
Part, 25 parts of olibanum, 13 parts of myrrh, 13 parts of first tail, 12 parts of Eupolyphoge sinensis, 13 parts of full worm, 12 parts of pheretima, 5 parts of centipede, black 5 parts of snake, dragon's blood
3 parts, 45 parts of vomiting nut.
Present embodiment treatment rheumatism bone disease drug the preparation method comprises the following steps: according to pharmaceutical formulation ratio Chinese ephedra 25
Part, river is 18 parts attached, 25 parts of olibanum, 13 parts of myrrh, 13 parts of first tail, 12 parts of Eupolyphoge sinensis, 13 parts of full worm, 12 parts of pheretima, 5 parts of centipede, crow
5 parts of snake, 3 parts of dragon's blood, 45 parts of vomiting nut be placed in water and boiled twice, it is small to boil one again for mild fire after each intense fire water is opened
When, it is mixed to get tanning medical fluid twice, boils and high spirit immersion is added in medical fluid, white wine is the wine of preferred pure grain brewing, white
The alcohol concentration of wine is 34-53 degree, wherein the volume ratio of tanning medical fluid and white wine is 20-25: 1, both obtains drug.
The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention.The technology of the industry
Personnel are it should be appreciated that the present invention is not limited to the above embodiments, and the above embodiments and description only describe this
The principle of invention, without departing from the spirit and scope of the present invention, various changes and improvements may be made to the invention, these changes
Change and improvement all fall within the protetion scope of the claimed invention.The claimed scope of the invention by appended claims and its
Equivalent thereof.
Claims (10)
1. a kind of drug for treating rheumatism bone disease, it is characterised in that: the drug of the treatment rheumatism bone disease includes following weight
Part raw material: 20-30 parts of Chinese ephedra, river be 15-20 parts attached, 20-30 parts of olibanum, 10-15 parts of myrrh, 10-15 parts of first tail, Eupolyphoge sinensis 8-15
Part, worm 10-15 parts complete, 8-15 parts of pheretima, 3-8 parts of centipede, black 3-8 parts of snake, 2-5 parts of dragon's blood, 40-50 parts of vomiting nut.
2. a kind of drug for treating rheumatism bone disease according to claim 1, it is characterised in that: the treatment rheumatism bone disease
Drug include following raw material: 25 parts of Chinese ephedra, river be 18 parts attached, 25 parts of olibanum, 13 parts of myrrh, 13 parts of first tail, Eupolyphoge sinensis 12
Part, 13 parts of full worm, 12 parts of pheretima, 5 parts of centipede, black 5 parts of snake, 3 parts of dragon's blood, 45 parts of vomiting nut.
3. a kind of drug for treating rheumatism bone disease according to claim 1, it is characterised in that described drug must not be
It is used.
4. a kind of drug for treating rheumatism bone disease according to claim 1, it is characterised in that described drug is any one
Described dosage form in kind pharmacy.
5. a kind of drug for treating rheumatism bone disease according to claim 4, it is characterised in that described medicament is solution
Or powder powder.
6. a kind of drug for treating rheumatism bone disease according to claim 1, it is characterised in that: the treatment rheumatism bone disease
Drug the preparation method comprises the following steps: according to pharmaceutical formulation ratio 25 parts of Chinese ephedra, river is 18 parts attached, 25 parts of olibanum, 13 parts of myrrh, first tail 13
Part, 12 parts of Eupolyphoge sinensis, 13 parts of full worm, 12 parts of pheretima, 5 parts of centipede, black 5 parts of snake, 3 parts of dragon's blood, 45 parts of vomiting nut be placed in water progress
It boils twice, mild fire boils one hour again after each intense fire water is opened, and is mixed to get tanning medical fluid twice.
7. the preparation method of the drug for the treatment of rheumatism bone disease according to claim 6, it is characterised in that: add in tanning medical fluid
Enter high spirit immersion, both obtains drug.
8. it is according to claim 7 treatment rheumatism bone disease drug preparation method, it is characterised in that: tanning medical fluid with it is white
The volume ratio of wine is 20-25: 1.
9. the preparation method of the drug for the treatment of rheumatism bone disease according to claim 7, it is characterised in that: the white wine is excellent
Select the wine of pure grain brewing.
10. the preparation method of the drug for the treatment of rheumatism bone disease according to claim 7, it is characterised in that: the white wine
Alcohol concentration is 34-53 degree.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710873206.9A CN109549997A (en) | 2017-09-25 | 2017-09-25 | A kind of drug for treating rheumatism bone disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710873206.9A CN109549997A (en) | 2017-09-25 | 2017-09-25 | A kind of drug for treating rheumatism bone disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109549997A true CN109549997A (en) | 2019-04-02 |
Family
ID=65862819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710873206.9A Pending CN109549997A (en) | 2017-09-25 | 2017-09-25 | A kind of drug for treating rheumatism bone disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109549997A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111743941A (en) * | 2020-07-24 | 2020-10-09 | 刘金龙 | Traditional Chinese medicine composition for treating rheumatoid bone diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530470A (en) * | 2009-04-24 | 2009-09-16 | 冯大海 | Medicament for treating rheumatism and rheumatoid disease, and preparing method thereof |
-
2017
- 2017-09-25 CN CN201710873206.9A patent/CN109549997A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530470A (en) * | 2009-04-24 | 2009-09-16 | 冯大海 | Medicament for treating rheumatism and rheumatoid disease, and preparing method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王薇薇: "中医治疗类风湿性关节炎浅述", 《中国中医药现代远程教育》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111743941A (en) * | 2020-07-24 | 2020-10-09 | 刘金龙 | Traditional Chinese medicine composition for treating rheumatoid bone diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103211932B (en) | Traditional Chinese medicine composition for treating rheumatism | |
| CN107137548A (en) | A kind of Chinese medicine composition for treating various osteopathy pains | |
| CN109549997A (en) | A kind of drug for treating rheumatism bone disease | |
| CN103251766A (en) | Chinese medicine composition, and clinical preparation and preparation method thereof | |
| CN102961539B (en) | Plaster for treating wind-cold-dampness arthralgia and preparation method thereof | |
| CN102526275B (en) | Pharmaceutical for curing gout and preparation method thereof | |
| CN113209182B (en) | A Chinese medicinal composition for treating rheumatoid arthritis, and its preparation method | |
| CN101554398B (en) | Externally applied medical ointment for treating surgical infection and gout and preparation method thereof | |
| CN102846750B (en) | Fengtongning composite preparation and preparation method thereof | |
| CN103272028B (en) | A kind of medicine for the treatment of traumatic injury and rheumatic arthralgia | |
| CN105770847A (en) | Traditional Chinese medicine composition for relieving or treating joint swelling and pain and preparation method and application of traditional Chinese medicine composition | |
| CN105796744A (en) | Toxin-removal traditional Chinese medicine ointment | |
| CN110478416A (en) | The composition and its preparation method and application for treating rheumatic rheumatoid arthritis | |
| CN104173679A (en) | Anti-rheumatoid medicinal liquor and preparation method thereof | |
| CN1084748A (en) | Quick results arthritis dressing and manufacture method thereof | |
| CN105641586A (en) | Fengtongning preparation and preparation method thereof | |
| CN1060388C (en) | Ointment for treating spur and its preparation method | |
| CN105943700A (en) | Traditional Chinese medicine composition capable of tonifying kidney and relieving paralysis and preparation method and application thereof | |
| CN104147576B (en) | A kind of external application medicated wine treating ischemic heart desease | |
| Jing et al. | Advances in the Application of State-target Dialectical Theory in the Treatment of Gouty Diseases | |
| CN105012600A (en) | External medicine for treating hyperostosis and herniated disk | |
| CN1190208C (en) | Exterior-applied medical salt for treating rheumatism | |
| CN104888147A (en) | Traditional Chinese medicine ointment for shoulder periarthritis and preparation method thereof | |
| CN104645067A (en) | Traditional Chinese medicine for treating gonarthromeningitis by matching with acupuncture and moxibustion | |
| CN103356965A (en) | Drug for curing rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190402 |